Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1056016.RA0hclecFn7k9SMts4qq9WEBLp8IevnJvHjOIF837ITMQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1056016.RA0hclecFn7k9SMts4qq9WEBLp8IevnJvHjOIF837ITMQ130_assertion type Assertion NP1056016.RA0hclecFn7k9SMts4qq9WEBLp8IevnJvHjOIF837ITMQ130_head.
- NP1056016.RA0hclecFn7k9SMts4qq9WEBLp8IevnJvHjOIF837ITMQ130_assertion description "[Treatment of established and patient-derived pancreatic cancer cell lines with the MEK1/2 inhibitor trametinib (GSK1120212) inhibited proliferation, and addition of the EGFR/HER2 inhibitor lapatinib enhanced the inhibition elicited by trametinib in three of eight cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1056016.RA0hclecFn7k9SMts4qq9WEBLp8IevnJvHjOIF837ITMQ130_provenance.
- NP1056016.RA0hclecFn7k9SMts4qq9WEBLp8IevnJvHjOIF837ITMQ130_assertion evidence source_evidence_literature NP1056016.RA0hclecFn7k9SMts4qq9WEBLp8IevnJvHjOIF837ITMQ130_provenance.
- NP1056016.RA0hclecFn7k9SMts4qq9WEBLp8IevnJvHjOIF837ITMQ130_assertion SIO_000772 23441129 NP1056016.RA0hclecFn7k9SMts4qq9WEBLp8IevnJvHjOIF837ITMQ130_provenance.
- NP1056016.RA0hclecFn7k9SMts4qq9WEBLp8IevnJvHjOIF837ITMQ130_assertion wasDerivedFrom befree-2016 NP1056016.RA0hclecFn7k9SMts4qq9WEBLp8IevnJvHjOIF837ITMQ130_provenance.
- NP1056016.RA0hclecFn7k9SMts4qq9WEBLp8IevnJvHjOIF837ITMQ130_assertion wasGeneratedBy ECO_0000203 NP1056016.RA0hclecFn7k9SMts4qq9WEBLp8IevnJvHjOIF837ITMQ130_provenance.